BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Authors
Keywords
-
Journal
Cancer Control
Volume 21, Issue 3, Pages 221-230
Publisher
SAGE Publications
Online
2017-08-30
DOI
10.1177/107327481402100307
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Clinical characteristics and outcomes with specificBRAFandNRASmutations in patients with metastatic melanoma
- (2013) Amanda D. Bucheit et al. CANCER
- Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer
- (2013) S. Cardarella et al. CLINICAL CANCER RESEARCH
- Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
- (2013) Mingzhao Xing et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation
- (2013) Javier Munoz et al. JOURNAL OF CLINICAL ONCOLOGY
- Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia
- (2013) Sascha Dietrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma
- (2013) Kerstin Trunzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer
- (2013) Charles M. Rudin et al. Journal of Thoracic Oncology
- Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib
- (2013) Oliver Gautschi et al. LUNG CANCER
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- BRAF V600E Inhibition in Anaplastic Thyroid Cancer
- (2013) Michael H. Rosove et al. NEW ENGLAND JOURNAL OF MEDICINE
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the BRAF V600E Mutation in Multiple Myeloma
- (2013) M. Andrulis et al. Cancer Discovery
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)
- (2012) K. A. Margolin et al. CLINICAL CANCER RESEARCH
- Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma
- (2012) M. A. Davies et al. CLINICAL CANCER RESEARCH
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
- (2012) A. M. Menzies et al. CLINICAL CANCER RESEARCH
- A combined oncogenic pathway signature ofBRAF,KRASandPI3KCAmutation improves colorectal cancer classification and cetuximab treatment prediction
- (2012) Sun Tian et al. GUT
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib
- (2012) Oliver Gautschi et al. Journal of Thoracic Oncology
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- BRAF Inhibition in Refractory Hairy-Cell Leukemia
- (2012) Sascha Dietrich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis
- (2012) Gholamreza Safaee Ardekani et al. PLoS One
- The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms
- (2011) L. Arcaini et al. BLOOD
- The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer
- (2011) Tae Hyuk Kim et al. CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
- (2011) S. Ogino et al. CLINICAL CANCER RESEARCH
- Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
- (2011) Cecily P. Vaughn et al. GENES CHROMOSOMES & CANCER
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
- (2011) Antonio Marchetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations
- (2011) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- BRAFMutations in Hairy-Cell Leukemia
- (2011) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)
- (2010) Joanna Xing et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
- (2010) K H T Paraiso et al. BRITISH JOURNAL OF CANCER
- Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis
- (2010) J.-H. Lee et al. BRITISH JOURNAL OF DERMATOLOGY
- BRAF in primary and recurrent papillary thyroid cancers: the relationship with 131I and 2-[18F]fluoro-2-deoxy-d-glucose uptake ability
- (2010) Susi Barollo et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Colorectal cancer
- (2010) David Cunningham et al. LANCET
- KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates
- (2010) Patrick A. Ott et al. PLoS One
- Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
- (2009) R. K. Amaravadi et al. CLINICAL CANCER RESEARCH
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
- (2009) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
- (2009) Richard T. Kloos et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
- (2009) C. A. Pratilas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- High-Resolution Melting Analysis for Rapid Detection ofKRAS, BRAF,andPIK3CAGene Mutations in Colorectal Cancer
- (2008) Lisa Simi et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
- (2008) C. A. Pratilas et al. CANCER RESEARCH
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel
- (2008) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel
- (2008) N. K. Haass et al. CLINICAL CANCER RESEARCH
- CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
- (2008) S. Ogino et al. GUT
- Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer
- (2008) Heather Hampel et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search